Summary
Background We investigated the safety, pharmacokinetics, tumor response, and immunological parameters of sorafenib plus interferon α-2a (IFN) in Japanese patients with advanced RCC. Patients and methods After 2 weeks of IFN-alone treatment, eligible patients received 28-day cycles of continuous sorafenib 200 mg (Cohort 1) or 400 mg (Cohorts 2 and 3) twice daily combined with intramuscular IFN 6 (Cohorts 1 and 2) or 9 (Cohort 3) million international units (MIU) three times a week. Results A total of 18 patients received at least one dose of sorafenib plus IFN. Five patients had dose-limiting toxicities (DLTs). The most common DLT was fatigue, experienced in four DLT patients. All 18 patients experienced at least one treatment-emergent adverse event (AE). The most common treatment-emergent AEs included fatigue, fever, platelets, leukocytes, hemoglobin, weight loss and anorexia. Five patients had confirmed partial response and 11 had stable disease, a response rate of 27.8%. IFN had no relevant impact on the pharmacokinetics of sorafenib. Conclusions Sorafenib administered in combination with IFN was well tolerated, with promising results in efficacy. Continuous sorafenib 400 mg twice daily in combination with IFN 6 MIU three times a week is recommended in Japanese patients with advanced RCC.
Similar content being viewed by others
References
Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875
McDermott DF, Atkins MB (2008) Immunotherapy of metastatic renal cell carcinoma. Cancer J 14:320–324
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134
Akaza H, Tsukamoto T, Murai M et al (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755–762
Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280–1289
Tochizawa S, Masumori N, Yanai Y et al (2008) Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. Biomed Res 29:271–278
Escudier B, Lassau N, Angevin E et al (2007) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13:1801–1809
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Minami H, Kawada K, Ebi H et al (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492–1498
Furuse J, Ishii H, Nakachi K et al (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159–165
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Glassman AB (1997) Hemostatic abnormalities associated with cancer and its therapy. Ann Clin Lab Sci 27:391–395
Funding
This research was sponsored by Bayer Yakuhin Ltd.
Conflicts of interest
Two of the co-authors, Koichi Fukino and Takahiko Tanigawa, are employees of Bayer Yakuhin Ltd.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Niwakawa, M., Hashine, K., Yamaguchi, R. et al. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Invest New Drugs 30, 1046–1054 (2012). https://doi.org/10.1007/s10637-010-9630-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9630-0